Senda Biosciences

Executive Summary

Senda Biosciences is a private biotech company pioneering programmable medicines using synthetic nanoparticles inspired by natural nanoparticles from all kingdoms of life. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company has raised $123 million to develop its platform that aims to precisely deliver a wide range of therapeutic payloads—including RNA and small molecules—to specific cells and tissues. By mimicking nature’s own delivery mechanisms, Senda seeks to overcome the key challenge of targeted delivery that limits many modern therapeutics, potentially enabling new classes of treatments for genetic and metabolic diseases. The platform-stage company has not yet disclosed specific pipeline programs, but its technology could have broad applicability across multiple therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Platform validation data from preclinical studies60% success
• Q4 2026Announcement of strategic partnership or licensing deal50% success